![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, February 14, 2023 3:32:37 PM
Bullish $axsm on yesterday’s news
Our take: While the news in itself (that a P-IV for Auvelity was filed) is not a surprise, the timing of the news does, as it comes a bit sooner than we have been expecting (note: given that Auvelity was initially filed for approval under the 505() (2) pathway, we had expected that a P4 could come at any point in time.
That said, we had an opportunity to speak with AXSM management this morning, who noted: (1) the P-IV has been expected by the company, and it was only a matter of time; (2) that TEVA filed a P-IV for Auvelity implies to them that TEVA thinks Auvelity will be a significant commercial product, (3) the earliest that a generic could be approved is in 2034, at least 11 years from now, giving Auvelity a sufficient commercial runway; (4) with >100 patents listed in the FDA's Orange Book, we should expect that AXSM will continue to strengthen its Auvelity IP estate; and (5) the company is still evaluating its patent term extension (PTE) strategy for Auvelity, which could potentially add additional patent protection.
Also this morning, we also had an opportunity to speak with an IP expert, a person we frequently use on IP diligence. In his view (and ours), that TEVA is only challenging four method of use patents expiring in 2040 (and not the base '328 and '234 patents which expire in 2033 and '34, respectively) represents a very favorable development for AXSM. That said, we'll be interested in learning more about TEVA's IP strategy (as well as AXSM's strategy in response) once AXSM's patent lawsuit against TEVA becomes available.
Bottom line: TEVA is not challenging the earlier expiring patents for Auvelity, and seeing this as a potential best case scenario for AXSM with respect to a potential loss of exclusivity/LOE for Auvelity (where recall, we currently model LOE in 2034), we're not terribly concerned about the news
Hence, on any_potential weakness, we recommend being opportunistic on AXSM shares today.
Graig Suvannavejh, Ph.D.
Managing Director
+1 212 282 4019
Graig.Suvannavejh@mizuhogroup.com
Please refer to the linked full report for important disclosure and analyst certification information
99+
Recent AXSM News
- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:31:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:38:42 AM
- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories • GlobeNewswire Inc. • 06/05/2024 11:35:00 AM
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month • GlobeNewswire Inc. • 06/04/2024 11:00:00 AM
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:12:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:11:32 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:24:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:23:38 PM
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 • GlobeNewswire Inc. • 05/29/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:28:52 PM
- Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting • GlobeNewswire Inc. • 05/28/2024 11:00:00 AM
- Axsome Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 09:20:33 PM
- Index Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices Rise • IH Market News • 05/06/2024 12:09:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 11:05:31 AM
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/06/2024 11:00:00 AM
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 • GlobeNewswire Inc. • 04/10/2024 11:00:00 AM
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients • GlobeNewswire Inc. • 03/25/2024 11:00:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM